Pfizer (PFE) Stock Value Declined While Wilkins Investment Counsel Trimmed Its Position by $2.62 Million; Enzo Biochem (ENZ) Shareholder Marathon Capital Management Has Upped Stake by $434,775 as Stock Value Declined

August 10, 2018 - By Clara Lewis

Pfizer Inc. (NYSE:PFE) Logo

Marathon Capital Management increased its stake in Enzo Biochem Inc (ENZ) by 33.78% based on its latest 2018Q1 regulatory filing with the SEC. Marathon Capital Management bought 86,955 shares as the company’s stock declined 1.79% with the market. The institutional investor held 344,404 shares of the health care company at the end of 2018Q1, valued at $1.89 million, up from 257,449 at the end of the previous reported quarter. Marathon Capital Management who had been investing in Enzo Biochem Inc for a number of months, seems to be bullish on the $196.21 million market cap company. The stock decreased 2.35% or $0.1 during the last trading session, reaching $4.16. About 52,644 shares traded. Enzo Biochem, Inc. (NYSE:ENZ) has declined 27.40% since August 10, 2017 and is downtrending. It has underperformed by 39.97% the S&P500. Some Historical ENZ News: 24/04/2018 – Patent Trial and Appeal Board Denies Hologic Challenge to Enzo Biochem Patent Involved in Delaware Infringement Case; 24/04/2018 – ENZO BIOCHEM INC – PATENT TRIAL AND APPEAL BOARD HAS DENIED A PETITION FILED BY HOLOGIC FOR INTER PARTES REVIEW; 24/04/2018 – Report: Exploring Fundamental Drivers Behind Enzo Biochem, The Hackett Group, Rexford Industrial Realty, Green Plains, United C; 24/04/2018 – ENZO: HOLOGIC CHALLENGING ENZO PATENT IN INFRINGEMENT CASE

Wilkins Investment Counsel Inc decreased its stake in Pfizer (PFE) by 28.36% based on its latest 2018Q1 regulatory filing with the SEC. Wilkins Investment Counsel Inc sold 74,902 shares as the company’s stock declined 3.80% with the market. The institutional investor held 189,212 shares of the health care company at the end of 2018Q1, valued at $6.72M, down from 264,114 at the end of the previous reported quarter. Wilkins Investment Counsel Inc who had been investing in Pfizer for a number of months, seems to be less bullish one the $238.45B market cap company. The stock decreased 0.58% or $0.2364 during the last trading session, reaching $40.7636. About 8.14 million shares traded. Pfizer Inc. (NYSE:PFE) has risen 10.95% since August 10, 2017 and is uptrending. It has underperformed by 1.62% the S&P500. Some Historical PFE News: 28/03/2018 – New top 10!~ Elephants can’t jump? IDEA’s Mike Rea says some Big Pharma players are crushing old beliefs @ideapharma $AZN $PFE $NVS; 26/04/2018 – PFIZER INC – DECLARES 34-CENT SECOND-QUARTER 2018 DIVIDEND; 08/05/2018 – EPIPEN MANUFACTURER PFIZER PFE.N SAYS APRIL EPIPEN SHIPMENTS EXCEEDED PROJECTIONS; 23/03/2018 – ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe; 29/03/2018 – PFIZER INC – PRELIMINARY SAFETY DATA SHOWED THAT TAFAMIDIS WAS GENERALLY WELL TOLERATED; 03/04/2018 – NEW: Pfizer in talks with P&G on the sale of its consumer business, but the companies are far apart on price, sources tell @DavidFaber; 09/04/2018 – Pfizer Canada and MaRS Innovation Partner to Convert Great Science into Solutions to Benefit Canadians’ Health; 21/05/2018 – Association of Community Cancer Centers and Pfizer Offer Grant Opportunities Focused on Improving Quality of Breast Cancer Care; 18/04/2018 – PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR CANCER COMBINATION THERAPY; 15/05/2018 – FDA OK’S HOSPIRA’S RETACRIT TREATMENT FOR ANEMIA

Wilkins Investment Counsel Inc, which manages about $365.32 million and $316.18M US Long portfolio, upped its stake in General Mills (NYSE:GIS) by 10,825 shares to 159,175 shares, valued at $7.17 million in 2018Q1, according to the filing. It also increased its holding in Medtronic Plc (NYSE:MDT) by 3,850 shares in the quarter, for a total of 98,395 shares, and has risen its stake in Chubb Limited.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Finance.Yahoo.com which released: “You Better Be Careful with Merck Stock, Especially at These Highs” on August 10, 2018, also Fool.com with their article: “Why Pfizer Stock Gained 10% in July” published on August 06, 2018, Seekingalpha.com published: “BeiGene launches late-stage study of tislelizumab in first-line lung cancer” on August 09, 2018. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “Pfizer: Keep On Reinvesting Dividends” published on July 24, 2018 as well as 247Wallst.com‘s news article titled: “Short Sellers Hike Bets in Major Pharma Stocks” with publication date: August 10, 2018.

Since February 24, 2018, it had 0 insider buys, and 14 sales for $19.59 million activity. $4.76 million worth of Pfizer Inc. (NYSE:PFE) was sold by READ IAN C. Another trade for 27,323 shares valued at $998,666 was sold by JOHNSON RADY A. CORNWELL W DON had sold 1,758 shares worth $64,679 on Monday, February 26. 26,779 shares were sold by HILL CHARLES H, worth $986,292 on Wednesday, February 28. $2.55M worth of Pfizer Inc. (NYSE:PFE) shares were sold by Dolsten Mikael. OLSON LAURIE J also sold $692,582 worth of Pfizer Inc. (NYSE:PFE) shares.

Investors sentiment decreased to 0.89 in Q1 2018. Its down 0.17, from 1.06 in 2017Q4. It fall, as 70 investors sold PFE shares while 718 reduced holdings. 104 funds opened positions while 595 raised stakes. 4.01 billion shares or 1.39% less from 4.07 billion shares in 2017Q4 were reported. Tompkins Corp holds 0.78% or 97,520 shares in its portfolio. C Gru Holding A S invested in 0.3% or 549,379 shares. Andra Ap has invested 0.14% in Pfizer Inc. (NYSE:PFE). Moreover, Wilbanks Smith And Thomas Asset has 0.42% invested in Pfizer Inc. (NYSE:PFE). Fairview Capital Invest Mngmt Llc has invested 0.02% in Pfizer Inc. (NYSE:PFE). Clarivest Asset Management Limited Company holds 0% or 254 shares in its portfolio. 177,971 are held by First Bancorp. Chatham Capital Gru Inc, a Georgia-based fund reported 30,197 shares. Central National Bank And Tru holds 37,268 shares. Sit Assocs Incorporated reported 1.04M shares or 0.91% of all its holdings. Evercore Wealth Management Limited Liability Corporation holds 0.25% or 183,794 shares in its portfolio. 16,500 are held by Main Street Ltd. 203,801 are owned by Transamerica Advsr. Mraz Amerine & Associates accumulated 9,922 shares. Blair William Il holds 0.23% of its portfolio in Pfizer Inc. (NYSE:PFE) for 912,169 shares.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on October, 30. They expect $0.75 earnings per share, up 11.94% or $0.08 from last year’s $0.67 per share. PFE’s profit will be $4.39 billion for 13.59 P/E if the $0.75 EPS becomes a reality. After $0.81 actual earnings per share reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -7.41% negative EPS growth.

Among 23 analysts covering Pfizer (NYSE:PFE), 10 have Buy rating, 1 Sell and 12 Hold. Therefore 43% are positive. Pfizer had 83 analyst reports since July 29, 2015 according to SRatingsIntel. Jefferies maintained Pfizer Inc. (NYSE:PFE) on Thursday, July 14 with “Buy” rating. The stock of Pfizer Inc. (NYSE:PFE) earned “Hold” rating by Jefferies on Thursday, July 13. The firm has “Buy” rating by Argus Research given on Tuesday, November 3. On Wednesday, July 29 the stock rating was maintained by Argus Research with “Buy”. Cowen & Co upgraded Pfizer Inc. (NYSE:PFE) rating on Tuesday, October 20. Cowen & Co has “Outperform” rating and $43 target. The stock of Pfizer Inc. (NYSE:PFE) has “Buy” rating given on Wednesday, October 28 by Deutsche Bank. Piper Jaffray maintained the shares of PFE in report on Friday, August 28 with “Overweight” rating. The company was downgraded on Thursday, October 13 by Jefferies. The company was downgraded on Thursday, July 20 by Credit Suisse. The rating was maintained by Jefferies on Wednesday, August 16 with “Hold”.

Investors sentiment increased to 1.26 in Q1 2018. Its up 0.39, from 0.87 in 2017Q4. It is positive, as 17 investors sold ENZ shares while 25 reduced holdings. 17 funds opened positions while 36 raised stakes. 26.26 million shares or 1.04% more from 25.99 million shares in 2017Q4 were reported. 25,357 were accumulated by Credit Suisse Ag. State Street Corp reported 0% in Enzo Biochem, Inc. (NYSE:ENZ). Prudential Incorporated has 0% invested in Enzo Biochem, Inc. (NYSE:ENZ). Gsa Capital Prtnrs Llp reported 0.04% in Enzo Biochem, Inc. (NYSE:ENZ). Tower Ltd Llc (Trc) stated it has 1,082 shares. Voya Ltd Liability Com owns 23,643 shares for 0% of their portfolio. Highbridge Cap Management Lc invested in 0% or 38,340 shares. New York State Common Retirement Fund stated it has 40,600 shares or 0% of all its holdings. Guggenheim Capital Lc reported 0% in Enzo Biochem, Inc. (NYSE:ENZ). D E Shaw Co has invested 0% in Enzo Biochem, Inc. (NYSE:ENZ). Bnp Paribas Arbitrage accumulated 0% or 10,211 shares. Deutsche Commercial Bank Ag stated it has 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). Panagora Asset owns 76,703 shares. 16,825 were reported by Federated Invsts Inc Pa. Neuberger Berman Ltd Liability Corp holds 0% or 22,613 shares.

More important recent Enzo Biochem, Inc. (NYSE:ENZ) news were published by: Nasdaq.com which released: “Market Trends Toward New Normal in Sandy Spring, Tupperware Brands, Dolby Laboratories, AeroVironment, Barnes …” on August 02, 2018, also Benzinga.com published article titled: “Benzinga’s Daily Biotech Pulse: Merck’s Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile”, Benzinga.com published: “The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo’s Positive Trial Results, Insys Earnings” on August 09, 2018. More interesting news about Enzo Biochem, Inc. (NYSE:ENZ) was released by: Benzinga.com and their article: “The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos’ Maiden Earnings, Paratek Awaits Adcom Verdict” with publication date: August 08, 2018.

Pfizer Inc. (NYSE:PFE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts